<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633372</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-230</org_study_id>
    <nct_id>NCT01633372</nct_id>
  </id_info>
  <brief_title>An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis</brief_title>
  <official_title>An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will
      evaluate safety and efficacy parameters of itacitinib (INCB039110).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with &gt;/= 50% reduction in total symptom score in each dose group, as measured by the modified The Myelofibrosis Symptom Assessment Form (MFSAF) v3.0 diary</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with &gt;/= 35% reduction in spleen volume, and mean percent change in spleen volume</measure>
    <time_frame>Baseline, Week 12 and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of transfusion dependent subjects who exhibit changes in transfusion frequency over any 12 week period on study and proportion of transfusion independent subjects who exhibit changes in hemoglobin level</measure>
    <time_frame>Baseline to Week 12; Week 13 to Week 24 through the end of study or study termination visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of itacitinib (INCB039110) as measured by adverse events.</measure>
    <time_frame>Every 4-6 weeks through the end of study or early termination visit (approximately 33 weeks exclusive of the extension phase).</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <arm_group>
    <arm_group_label>itacitinib (INCB039110) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>itacitinib (INCB039110) 100 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>itacitinib (INCB039110) 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>itacitinib (INCB039110) 200 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>itacitinib (INCB039110) 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>itacitinib (INCB039110) 300 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>itacitinib (INCB039110) 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>itacitinib (INCB039110) 400 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>itacitinib (INCB039110) 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>itacitinib (INCB039110) 600 mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itacitinib</intervention_name>
    <arm_group_label>itacitinib (INCB039110) 100 mg</arm_group_label>
    <arm_group_label>itacitinib (INCB039110) 200 mg</arm_group_label>
    <arm_group_label>itacitinib (INCB039110) 300 mg</arm_group_label>
    <arm_group_label>itacitinib (INCB039110) 400 mg</arm_group_label>
    <arm_group_label>itacitinib (INCB039110) 600 mg</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy.

          -  Must score at least 1 point on the Dynamic International Prognostic Scoring System
             (DIPSS) for prognostic risk factors and have peripheral blast count &lt;10% at both
             Screening and Baseline hematology assessments.

          -  Subjects must discontinue all drugs used to treat underlying MF disease no later than
             Day -14.

          -  Subjects must have hemoglobin value &gt;/= 8.0g/dL and be willing to receive blood
             transfusions, have a platelet count &gt;/=50x10^9/L and absolute neutrophil count (ANC)
             &gt;/= 1x10^9/L.

          -  Subjects must have palpable spleen or history of splenectomy

          -  Active symptoms at the screening visit

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding, and men and women who cannot comply with
             requirements to avoid fathering a child or becoming pregnant, respectively.

          -  Subjects with impaired liver function, end stage renal disease on dialysis or
             clinically significant concurrent infections requiring therapy.

          -  Subjects with unstable cardiac function or invasive malignancies over the previous 2
             years except treated basal or squamous carcinomas of the skin, completely resected
             intraepithelial carcinoma of the cervix and completely resected papillary thyroid and
             follicular thyroid cancers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Assad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology Oncology Associates, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology &amp; Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Baskin Cancer Foundation, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <disposition_first_submitted>March 26, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 22, 2014</disposition_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Myelofibrosis</keyword>
  <keyword>PMF</keyword>
  <keyword>Post Polycythemia Vera Fibrosis</keyword>
  <keyword>PPV-MF</keyword>
  <keyword>Post Essential Thrombocythemia Myelofibrosis</keyword>
  <keyword>PET-MF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

